37 research outputs found
ACTION PR�VENTIVE ?UN ANTIHISTAMINIQUE D�RIV� DE LA THIODI-PH�NYLAMINE SUR ?OED�ME AIGU DU POUMON EXP�RIMENTAL
The heart and the aorta; studies in clinical radiology.
Bibliography: p. [250]-251.Mode of access: Internet
Dynamic evaluation of tumoral transcriptome for a blind study of mechanisms of chemoradiotherapy resistance in rectal cancer patients
Ring distraction technique for measuring surface tension of sputum: relationship to sputum clearability
Stabilization of the P(CF3)(2)(-) ion as a reversible CS2 adduct, [P(CF3)(2)CS2](-), and its potential use as a nucleophilic P(CF3)(2)(-) source: Synthesis and structure of [18-Crown-6-K][P(C6F5)(2)CS2]
Hoge B, Thosen C, Herrmann T, Pantenburg I. Stabilization of the P(CF3)(2)(-) ion as a reversible CS2 adduct, [P(CF3)(2)CS2](-), and its potential use as a nucleophilic P(CF3)(2)(-) source: Synthesis and structure of [18-Crown-6-K][P(C6F5)(2)CS2]. INORGANIC CHEMISTRY. 2002;41(8):2260-2265
Comparison of mechanical and degradation properties of EG and EGDMA grafted gelatin films
Synthesis and Development of Four Way Catalysts Starting from Critical Raw Material Free Perovskites: Influence of Doping and Synthesis Conditions
Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study.
Under the auspices of an International Working Group, seven centers submitted diagnostic and follow-up information on 1545 patients with World Health Organization-defined polycythemia vera (PV). At diagnosis, median age was 61 years (51% females); thrombocytosis and venous thrombosis were more frequent in women and arterial thrombosis and abnormal karyotype in men. Considering patients from the center with the most mature follow-up information (n=337 with 44% of patients followed to death), median survival (14.1 years) was significantly worse than that of the age- and sex-matched US population (P<0.001). In multivariable analysis, survival for the entire study cohort (n=1545) was adversely affected by older age, leukocytosis, venous thrombosis and abnormal karyotype; a prognostic model that included the first three parameters delineated risk groups with median survivals of 10.9-27.8 years (hazard ratio (HR), 10.7; 95% confidence interval (CI): 7.7-15.0). Pruritus was identified as a favorable risk factor for survival. Cumulative hazard of leukemic transformation, with death as a competing risk, was 2.3% at 10 years and 5.5% at 15 years; risk factors included older age, abnormal karyotype and leukocytes 15 × 10(9)/l. Leukemic transformation was associated with treatment exposure to pipobroman or P32/chlorambucil. We found no association between leukemic transformation and hydroxyurea or busulfan use